Reporting of adverse effects of intradermal vs. intranodal administration of tolDC to investigators, data safety monitoring board and regulatory authorities

We anticipate timely, accurate, and complete reporting and analysis of safety information. Adverse events will be summarised by presenting for each cohort, the number and proportion of patients having an adverse event.